[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endocarditis-infective\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endocarditis-infective":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,69,92,113,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053220","phase-3-dalbavancin-therapy-for-infective-endocarditis-100053220",false,"NCT07699211","Dalbavancin Therapy for Infective Endocarditis","Efficacy and Safety of Dalbavancin in the Treatment of Infective Endocarditis Caused by Gram-Positive Cocci","EndoDalba","Inclusion Criteria:\n\n1. ≥ 18 years\n2. written informed consent\n3. Confirmed left-sided infective endocarditis (mitral and\u002For aortic valve) involving native (NV) or prosthetic (PV) valves caused by Gram-positive cocci (staphylococci, streptococci, or enterococci) that are susceptible to dalbavancin.\n\nExclusion Criteria:\n\n1. Hemodynamic instability requiring vasopressor therapy within the last 72 hours prior to randomization\n2. Body temperature ≥38.0°C within the 72 hours prior to randomization\n3. Evidence of pathogen growth in a blood culture within the 72 hours prior to randomization\n4. Presence of a cardiac abscess at the time of randomization\n5. Presence of a remaining infected cardiovascular implantable electronic device (CIED), an infected intravascular graft, or an infected TAVI prosthesis (\"TAVI endocarditis\") at the time of randomization\n6. Duration of effective intravenous antibiotic therapy for endocarditis of \\\u003C 7 days prior to randomization\n7. Remaining duration of required antibiotic therapy for the treatment of endocarditis is less than 10 days (i.e., remaining treatment duration must be at least 10 days)\n8. Hypersensitivity to dalbavancin, vancomycin, teicoplanin, or other components of the investigational drug\n9. Participation in another clinical interventional trial under the German Medicines Act (AMG), Medical Devices Regulation (MDR), or Medical Devices Act (MPDG) without prior consultation and approval by the respective sponsors prior to randomization\n10. Continuous renal replacement therapy (e.g., CVVHD, CVVHDF)\n11. Child B or C liver cirrhosis\n12. Palliative care\n13. Secondary infections requiring a longer course of antibiotic therapy than that intended for the treatment of endocarditis\n14. Oral antibiotic therapy already initiated to treat the current episode of endocarditis\n15. Scheduled cardiac surgery after randomization, within the period designated for antibiotic treatment of endocarditis\n16. Intraspinal or brain abscess (\\> 0.5 cm)\n17. Pregnant and breastfeeding women\n18. Women of childbearing potential, unless the following criteria are met:\n\n    1. Postmenopausal (12 months of natural amenorrhea or 6 months of amenorrhea with serum FSH \\> 40 mIU\u002FmL)\n    2. Postoperative (6 weeks after bilateral oophorectomy with or without hysterectomy)\n    3. Regular and correct use of a contraceptive method with a failure rate \\\u003C 1% per year (considered reliable contraceptive methods include oral hormonal contraception, dermal hormonal contraception, contraceptive patches, long-acting injectable contraceptives, progesterone-releasing implants (Implanon®), intramuscular progesterone, tubal ligation (female sterilization), hormone-releasing intrauterine device (\"hormonal IUD\"), dual barrier methods)\n    4. sexual abstinence\n    5. Vasectomy of the partner","ALL","18 Years",{"count":20,"type":21},184,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study compares two treatment strategies for antibiotic therapy in endocarditis. The aim of the study is to determine which treatment is more effective overall and better tolerated by patients.\n\nThe first strategy is standard therapy: treatment with proven antibiotics, which are usually administered initially as an intravenous infusion in the hospital and can be switched to oral therapy with tablets later on for suitable patients.\n\nThe second strategy is the study treatment with dalbavancin: This is a long-acting antibiotic. It is administered as a single infusion; for longer treatment durations, a second infusion may be necessary 14 days later.",[27,28],"Endocarditis Infective","Endocarditis, Bacterial",[30,31],"Infective Endocarditis","Dalbavancin","NOT_YET_RECRUITING","2026-07-09",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":21},"2026-12",{"date":40,"type":21},"2029-12",{"name":42,"class":43},"Stefan Hagel","OTHER",9,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100302042","study-of-the-prognosis-of-infectious-endocarditis-epei-100302042","NCT03211975","Study of the Prognosis of Infectious Endocarditis (EPEI)","Study of the Prognosis of Infectious Endocarditis (EPEI): Prospective and Retrospective Follow-up of a Cohort of Patients Hospitalized for Infectious Endocarditis","EPEI","Inclusion Criteria:\n\n* all patients with certain infectious endocarditis according to Duke's criteria, confirmed by the presence of evocative images on the transthoracic and \u002F or transesophageal ultrasound or by the data collected on the surgical specimens.\n\nExclusion Criteria:\n\n* Patients with an infection not meeting the Duke IE criteria.",{"count":54,"type":21},645,"OBSERVATIONAL","Infectious endocarditis (IE) is the localization and proliferation of blood-borne germs in the endocardium. It remains a complicated disease to manage due to its low incidence, diagnostic difficulties, the change in epidemiology in recent decades and high mortality rates. The annual incidence is estimated at 3-10 cases per 100,000 people.\n\nThe epidemiology of AR has changed significantly in recent years due to new risk factors. Indeed, the frequency of rheumatic heart disease, which was the first predisposing factor, decreased markedly in the industrialized countries, replaced by new predisposing factors: the presence of valvular prostheses or intracardiac materials (the risk of AR is multiplied by 50 Compared with the general population), hemodialysis, nosocomial infections, immunosuppression, increased use of injectable treatments and, above all, an aging population with an increase in degenerative diseases such as aortic stenosis and l Mitral insufficiency.\n\nThe diagnosis of IA is based on DUKE criteria. But the clinical presentation is sometimes atypical especially in case of infection on prosthesis where the diagnosis is based mainly on the results of the blood cultures and the ultrasound data.\n\nThe lesions visualized in ultrasound are: vegetations, abscesses, pseudo-aneurysms and fistulas constituting the degenerated abscess evolution, the perforation of the cusps of the native valve or the bioprosthesis giving rise to a jet of Eccentric regurgitation.\n\nThe evolution of endocarditis and its prognosis vary according to many factors: the type of germ responsible, the precocity of the diagnosis, the existence of a complication, the site of occurrence. These complications of endocarditis are frequent, sometimes revealing. EI is complicated by heart failure, atrioventricular conduction disorders, peri-vascular abscesses, embolic, neurological, renal and septic complications. Despite improvements in diagnosis and therapeutic methods, diagnosis is sometimes difficult, management remains very complicated and morbidity and mortality remain high. Studies are still needed to study the prognosis and to determine the predictive factors for hospital mortality and long-term mortality.",[27],"RECRUITING","2026-06-12",{"date":61,"type":36},"2026-06-15",{"date":63,"type":36},"2017-02-27",{"date":65,"type":21},"2026-06",{"name":67,"class":43},"Centre Hospitalier Universitaire, Amiens",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100469889","phase-4-oral-antimicrobial-treatment-vs-outpatient-parenteral-for-infective-endocarditis-100469889","NCT05398679","Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","OraPAT-IEGAMES","Inclusion Criteria:\n\n* Left-sided native or prosthetic infective endocarditis based on the modified Duke criteria infected with one of the following nonresistant microorganisms: Non-resistant streptococci and other gram positive cocci,e.g., Granulicatella and Abiotrophia; Enterococcus faecalis; Staphylococcus aureus;coagulase-negative staphylococci and HACEK group.\n* Male or female 18 years old or older.\n* 10 days or more of appropriate parenteral antibiotic treatment overall and at least one week of appropriate parenteral treatment after value surgery.\n* Temperature inferior to 38ºC for more than two days. 5. C-reactive protein dropped to \\\u003C25% of peak value or \\\u003C20 mg\u002Fl, and white blood cell count \\\u003C15x10\\^9\u002Fl during antibiotic treatment\n* Transthoracic \u002F transesophageal echocardiography performed within 48 hours of randomization\n\nExclusion Criteria:\n\n* Body mass index \\>40\n* Concomitant infection requiring intravenous antibiotic therapy\n* Inability to give informed consent to participation\n* Suspicion of reduced absorption of oral treatment due to abdominal disorder\n* Microorganisms with no oral combinations for treatment (two active antibiotics of different families)\n* Any immunosuppressive disease or any medical condition at the discretion of the investigator that may preclude oral or OPAT therapy\n* No family or appropriate home support\n* Reduced compliance\n* Women of childbearing potential with a positive pregnancy test, or participants (male or female) who wish to plan a pregnancy during the trial period\n* Women in lactancy period",{"count":77,"type":21},360,[79],"PHASE4","Non-inferiority trial to determine whether partial oral treatment is non-inferior to OPAT(Outpatient parenteral therapy) in patients diagnosed with infective endocarditis",[27],"2026-02-23",{"date":84,"type":36},"2026-02-25",{"date":86,"type":36},"2022-08-17",{"date":88,"type":21},"2027-12-30",{"name":90,"class":43},"Fundacion Clinic per a la Recerca Biomédica",20,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100624879","transthoracic-echocardiography-in-assessing-patients-with-suspected-endocarditis-100624879","NCT07415369","Transthoracic Echocardiography in Assessing Patients With Suspected Endocarditis","Transthoracic Echocardiography in Assessing Patients With Suspected Endocarditis - Prospective Study","TEASE-Forward","Inclusion Criteria:\n\n* age over 18 years;\n* patients who underwent transoesophageal echocardiography (TOE) for suspected infective endocarditis within 15 days of a transthoracic exam (TTE).\n\nExclusion Criteria:\n\n\\- diagnosis of endocarditis was made in another center.",{"count":101,"type":21},350,"This single-center, prospective observational study evaluates the accuracy of transthoracic echocardiography (TTE) to rule out infective endocarditis (IE) in patients with suspected IE, with the goal of reducing unnecessary transesophageal echocardiography (TOE), a more invasive diagnostic test.\n\nEligible patients are those admitted to the Department of Cardiovascular Sciences at Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Rome, Italy) who undergo TOE for suspected IE within 15 days of a TTE.\n\nClinical, laboratory, and echocardiographic variables will be collected to characterize the study population and support analyses of diagnostic performance and in-hospital outcomes.",[27],"2026-02-12",{"date":106,"type":36},"2026-02-17",{"date":108,"type":21},"2026-03",{"date":110,"type":21},"2027-04",{"name":112,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":121,"studyType":55,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":68},"100619561","san-matteo-endocarditis-registry-steady-100619561","NCT07346222","San Matteo Endocarditis Registry STEADY","Inclusion Criteria:\n\n* All patients admitted from 1stJannary 2009 to 31 Dec 2029 to the Fondazione IRCCS Policlinico San Matteo with a diagnosis of IE according to modified Duke criteria\n\nExclusion Criteria:\n\n\\-",{"count":120,"type":21},418,"10 Years","The general objective of this study is to deepen the knowledge of patients affected by endocarditis.",[27],"2026-01-08",{"date":126,"type":36},"2026-01-16",{"date":128,"type":36},"2020-08-20",{"date":130,"type":21},"2030-11-13",{"name":132,"class":43},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100548661","phase-4-ampicillin-and-ceftriaxone-for-the-treatment-of-enterococcus-faecalis-infective-endocarditis-100548661","NCT06423898","Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.","Efficacy and Safety of Ampicillin and Ceftriaxone Continuous Infusion Versus Standard Therapy for the Treatment of Enterococcus Faecalis Infective Endocarditis (DOβLEI Study)","DOBLEI","Inclusion Criteria:\n\n* Adult patients\n* Possible or definitive diagnosis of infective endocarditis due to Enterococcus faecalis\n* Signed informed consent of patients\n\nExclusion Criteria:\n\n* Allergy to penicillins or cephalosporins\n* Pregnancy and lactation\n* Polymicrobial infection including microorganisms different to E. faecalis",{"count":142,"type":21},284,[79],"Phase IV, open-label, randomized and multicenter clinical trial to prove that patients with Enterococcus faecalis infective endocarditis treated with an antibiotic treatment as a continuous infusion is non-inferior to the standard treatment, usually administered in hospitalized patients.",[146],"Endocarditis, Infective",[146,148,149,150,151],"Enterococcus faecalis","Antibiotics","Outpatient Infusion Therapies","Outpatient Care","2025-07-24",{"date":154,"type":36},"2025-07-25",{"date":156,"type":36},"2024-10-09",{"date":158,"type":21},"2028-12-31",{"name":160,"class":43},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla",18]